US22053A1079 - Common Stock
QUINCE THERAPEUTICS INC
NASDAQ:QNCX (5/10/2024, 7:15:24 PM)
0.95
+0.03 (+3.26%)
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 21 full-time employees. The company went IPO on 2019-05-09. The firm is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. The Company’s asset, EryDex, is being developed for the treatment of a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). EryDex utilizes a technology platform for autologous intracellular drug encapsulation (AIDE). Its proprietary AIDE technology is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once-monthly treatment period. The firm is also designed to allow for the chronic administration of the therapeutic. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics. The firm also intends to investigate additional potential applications of the AIDE technology platform.
QUINCE THERAPEUTICS INC
601 Gateway Boulevard, Suite 1250
South San Francisco CALIFORNIA
P: 14159105717
Employees: 21
Website: https://quincetx.com/
Quince Therapeutics just reported results for the fourth quarter of 2023.
Here you can normally see the latest stock twits on QNCX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: